Spots Global Cancer Trial Database for poziotinib
Every month we try and update this database with for poziotinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Trial to Evaluate the Efficacy of Poziotinib, Pan HER Inhibitor in Recurrent/Metastatic Esophageal Cancer (R/M ESCC) | NCT03770988 | Inoperable or R... | Treatment with ... | 20 Years - | Yonsei University | |
| Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC | NCT03066206 | EGFR Exon 20 Mu... ERBB2 Gene Muta... Recurrent Lung ... Stage IV Non-Sm... | Poziotinib | 18 Years - | M.D. Anderson Cancer Center | |
| Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation | NCT04044170 | NSCLC | Poziotinib | 18 Years - | Hanmi Pharmaceutical Company Limited | |
| Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation | NCT03318939 | NSCLC | Poziotinib | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway | NCT02544997 | Metastatic Brea... | Poziotinib | 20 Years - | Samsung Medical Center | |
| A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer | NCT03429101 | Breast Cancer | Poziotinib T-DM1 | 18 Years - 90 Years | Spectrum Pharmaceuticals, Inc | |
| Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation | NCT04044170 | NSCLC | Poziotinib | 18 Years - | Hanmi Pharmaceutical Company Limited | |
| A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway | NCT02544997 | Metastatic Brea... | Poziotinib | 20 Years - | Samsung Medical Center | |
| Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC | NCT03066206 | EGFR Exon 20 Mu... ERBB2 Gene Muta... Recurrent Lung ... Stage IV Non-Sm... | Poziotinib | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer | NCT03429101 | Breast Cancer | Poziotinib T-DM1 | 18 Years - 90 Years | Spectrum Pharmaceuticals, Inc | |
| Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001) | NCT02979821 | HER2 Gene Mutat... Adenocarcinoma ... | Poziotinib | - | Korean Association for the Study of Targeted Therapy | |
| A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib | NCT03744715 | NSCLC Breast Cancer | Poziotinib | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer | NCT03429101 | Breast Cancer | Poziotinib T-DM1 | 18 Years - 90 Years | Spectrum Pharmaceuticals, Inc | |
| Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation | NCT03318939 | NSCLC | Poziotinib | 18 Years - | Spectrum Pharmaceuticals, Inc |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
